|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
Datamonitor, July 2005, Pages: 145
Introduction
With annual revenues of over $2.6 billion in 2004, and a compound annual growth rate of 36.7% since 2002, the ADHD market is one of the most rapidly growing CNS markets. This growth is primarily attributed to the launches of several novel, once-daily ADHD therapies initially in the US and then periodically across the remaining major markets since 2000.
Scope
Overview of current market including profiles of key brands and key events impacting each brand during 2004-2005
Assessment of current and future opportunities and threats in the ADHD market across the seven major pharmaceutical markets
Global sales for leading ADHD products from 2002-2004 are presented, with projections for future performance up to 2015
In-depth discussion of assumptions and events used in forecast analysis
Highlights
US revenue growth within the ADHD market follows a distinct annual cycle, with the highest revenue growth occurring in August and September, coinciding with the end of the school summer vacation. Manufacturers wishing to maximize revenue potential on drug launch should therefore take advantage of this period of high drug revenue growth.
Drugs licensed for the treatment of adult ADHD are driving growth in this sector of the market, and derive significantly greater revenue shares as compared to drugs that are used off-label. We believe that now is an ideal time for manufacturers to gain approval for adult ADHD in the US, and enter this expanding market.
Strattera was the most rapidly growing drug in the US ADHD market with 2004 revenues of $632m, However, Q1 2005 revenues of the drug fell by 25.1% over Q4 2004, as a result of a product warning and other adverse market events. Nevertheless, We forecast that Strattera will bounce back and become market leader form 2007 onwards.
Reasons to Purchase
Assess leading ADHD drugs and identify key success factors within this sector
Understand key market drivers and predict the future performance of key compounds
Benchmark pipeline ADHD drugs against currently marketed products and assess their future market potential
Customers who bought this item also bought
Adult ADHD - Strattera Grows Up
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
Adhd Market: Pestel Analysis and Scenario Based Forecasts
ADHD & Insomnia Treatments
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
US market size for attention deficit / hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, number of prescriptions and ADHD drug sales in US dollars for 1999 forecast to 2004, with breakdown of dollar sales, Rx numbers and
US market size for attention deficit hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, by number of ADHD prescriptions and by dollar value of ADHD pharmaceutical sales; breakout of percent market share, number of prescrip
The ADD and ADHD Cure: The Natural Way to Treat Hyperactivity and Refocus Your Child
Launch Strategies - Analyzing Market Trends and Regulatory Impacts
|
|
|
|
